File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy

TitleBioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
Authors
KeywordsBiomarkers
Breast neoplasms
HER2
Lapatinib
Trastuzumab
Issue Date2019
PublisherKorean Cancer Association. The Journal's web site is located at https://www.e-crt.org/
Citation
Cancer Research and Treatment, 2019 How to Cite?
AbstractPurpose: BioPATH is a non-interventional study evaluating the relationship of molecular biomarkers (PTEN deletion/downregulation, PIK3CA mutation, truncated HER2 receptor [p95HER2], and tumor HER2 mRNA levels) to treatment responses in Asian patients with HER2+ advanced breast cancer treated with lapatinib and other HER2-targeted agents. Materials and Methods: Female Asian HER2+ breast cancer patients (n=154) who were candidates for lapatinib-based treatment following metastasis and having an available primary tumor biopsy specimen were included. The primary endpoint was progression-free survival (PFS). Secondary endpoints were response rate, overall survival on lapatinib, correlation between biomarker status and PFS for any previous trastuzumab-based treatment, and conversion/conservation rates of the biomarker status between tissue samples collected at primary diagnosis and at recurrence/metastasis. Potential relationships between tumor mRNA levels of HER2 and response to lapatinib-based therapy were also explored. Results: p95HER2, PTEN deletion/downregulation and PIK3CA mutation did not demonstrate any significant co-occurrence pattern and were not predictive of clinical outcomes on either lapatinib-based treatment or any previous trastuzumab-based therapy in the metastatic setting. Proportions of tumors positive for p95HER2 expression, PIK3CA mutation, and PTEN deletion/down-regulation at primary diagnosis were 32%, 31.2%, and 56.2%, respectively. Despite limited availability of paired samples, biomarker status patterns were conserved in most samples. HER2 mRNA levels were not predictive of PFS on lapatinib. Conclusion: The prevalence of p95HER2 expression, PIK3CA mutation, and PTEN deletion/downregulation at primary diagnosis were similar to previous reports. Importantly, no difference was observed in clinical outcome based on the status of these biomarkers, consistent with reports from other studies.
DescriptionEpub
Persistent Identifierhttp://hdl.handle.net/10722/273924
ISSN
2017 Impact Factor: 3.23
2015 SCImago Journal Rankings: 1.840

 

DC FieldValueLanguage
dc.contributor.authorKim, SB-
dc.contributor.authorDo, IG-
dc.contributor.authorTsang, J-
dc.contributor.authorKim, TY-
dc.contributor.authorYap, YS-
dc.contributor.authorCornelia, G-
dc.contributor.authorGong, G-
dc.contributor.authorPaik, S-
dc.contributor.authorLee, S-
dc.contributor.authorNg, TY-
dc.contributor.authorPark, S-
dc.contributor.authorOh, HS-
dc.contributor.authorChiu, J-
dc.contributor.authorSohn, J-
dc.contributor.authorLee, M-
dc.contributor.authorChoi, YJ-
dc.contributor.authorLee, EM-
dc.contributor.authorPark, KH-
dc.contributor.authorNathaniel, C-
dc.contributor.authorRo, J-
dc.date.accessioned2019-08-18T14:51:25Z-
dc.date.available2019-08-18T14:51:25Z-
dc.date.issued2019-
dc.identifier.citationCancer Research and Treatment, 2019-
dc.identifier.issn1598-2998-
dc.identifier.urihttp://hdl.handle.net/10722/273924-
dc.descriptionEpub-
dc.description.abstractPurpose: BioPATH is a non-interventional study evaluating the relationship of molecular biomarkers (PTEN deletion/downregulation, PIK3CA mutation, truncated HER2 receptor [p95HER2], and tumor HER2 mRNA levels) to treatment responses in Asian patients with HER2+ advanced breast cancer treated with lapatinib and other HER2-targeted agents. Materials and Methods: Female Asian HER2+ breast cancer patients (n=154) who were candidates for lapatinib-based treatment following metastasis and having an available primary tumor biopsy specimen were included. The primary endpoint was progression-free survival (PFS). Secondary endpoints were response rate, overall survival on lapatinib, correlation between biomarker status and PFS for any previous trastuzumab-based treatment, and conversion/conservation rates of the biomarker status between tissue samples collected at primary diagnosis and at recurrence/metastasis. Potential relationships between tumor mRNA levels of HER2 and response to lapatinib-based therapy were also explored. Results: p95HER2, PTEN deletion/downregulation and PIK3CA mutation did not demonstrate any significant co-occurrence pattern and were not predictive of clinical outcomes on either lapatinib-based treatment or any previous trastuzumab-based therapy in the metastatic setting. Proportions of tumors positive for p95HER2 expression, PIK3CA mutation, and PTEN deletion/down-regulation at primary diagnosis were 32%, 31.2%, and 56.2%, respectively. Despite limited availability of paired samples, biomarker status patterns were conserved in most samples. HER2 mRNA levels were not predictive of PFS on lapatinib. Conclusion: The prevalence of p95HER2 expression, PIK3CA mutation, and PTEN deletion/downregulation at primary diagnosis were similar to previous reports. Importantly, no difference was observed in clinical outcome based on the status of these biomarkers, consistent with reports from other studies.-
dc.languageeng-
dc.publisherKorean Cancer Association. The Journal's web site is located at https://www.e-crt.org/-
dc.relation.ispartofCancer Research and Treatment-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectBiomarkers-
dc.subjectBreast neoplasms-
dc.subjectHER2-
dc.subjectLapatinib-
dc.subjectTrastuzumab-
dc.titleBioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy-
dc.typeArticle-
dc.identifier.emailChiu, J: jwychiu@hku.hk-
dc.identifier.authorityChiu, J=rp01917-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.4143/crt.2018.598-
dc.identifier.pmid31163957-
dc.identifier.hkuros301144-
dc.publisher.placeKorea, Republic of-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats